Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
PubMed Central PMCID: PMC5410265
conjugation and transport
321(7):419-24
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach
Sitravatinib Catalog No.:M14117-2 PubMed Central PMCID: PMC5410265Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1. 5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0. 5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single agent antitumor efficacy and enhances the activity of PD 1 blockade through promoting an antitumor immune microenvironment. Product information CAS Number:
US$ 48.00
US$ 68.00
US$ 38.00
US$ 38.00
US$ 62.00
US$ 38.00
US$ 57.95